Andere Sprachen NurExone Biologic Inc.

Aktien

A3DNSU

CA67059R1091

NRX

Markt geschlossen - Toronto S.E. Andere Börsenplätze 15:38:14 23.05.2024			% 5 Tage	% 1. Jan.
0,48 ^CAD	0,00 %		-5,88 %	+62,71 %

25.04.	NurExone Biologic meldet OTCQB-Notierung und DTC-Zulassung	MT
02.04.	NurExone Biologic Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	17.05.
NurExone Biologic Announces OTCQB Listing And DTC Eligibility	25.04.
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	25.04.
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	22.04.
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	19.04.
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02.04.
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	02.04.
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	27.03.
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	22.03.
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	15.03.
NurExone Biologic Building a Research and Development Facility in Israel	08.03.
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	08.03.
NurExone Biologic Inc. Establishes Research and Development Facility in Haifa, Israel	08.03.
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	01.03.
NurExone’s Intellectual Property Portfolio Expands	20.02.
NurExone Biologic Inc. Expands Intellectual Property Portfolio	20.02.
NurExone Launches Licensing Efforts For ExoTherapy Platform	14.02.
NurExone Launches Licensing Efforts for ExoTherapy Platform	14.02.
NurExone Biologic Inc. Launches Licensing Efforts for ExoTherapy Platform	14.02.
NurExone Biologic Provides Operations Update	20.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NurExone Biologic Inc.

Aktien

A3DNSU

CA67059R1091

NRX

Andere Sprachen

Filter